Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/5-MeO-DMT/Equity and Ethics

5-MeO-DMT for Equity and Ethics

1 paper and 0 clinical trials exploring 5-meo-dmt as a treatment for equity and ethics.

CompoundTryptamine

5-MeO-DMT

A potent tryptamine psychedelic known for profound mystical experiences, currently under clinical investigation for TRD and anxiety.

Full 5-MeO-DMT profile
IndicationApproximately 1 in 4 adults experience mental health disorders annually worldwide.

Equity and Ethics

Equity and ethics in psychedelic research is a vital and complex topic, addressing the need for fair access and representation in clinical trials, as well as the stewardship of traditional knowledge. The involvement of Indigenous communities, who have historically used these substances, must be safeguarded against exploitation as the field matures.

Full Equity and Ethics profile

Academic Research

1 paper
Paywallmeta

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis

This systematic review and meta‑analysis of 214 studies (3,504 participants with analysable adverse‑event data) found that high‑dose classic psychedelics were generally well tolerated in clinical/research settings, with serious adverse events occurring mainly in ~4% of participants who had preexisting neuropsychiatric disorders and no reports in contemporary trials of suicide, persistent psychotic disorder or hallucinogen‑persisting perception disorder. Common non‑serious adverse events (headache, anxiety, nausea, fatigue, dizziness) had similar prevalences for psilocybin and LSD, but substantial heterogeneity and limited systematic adverse‑event monitoring across studies highlight the need for improved pharmacovigilance.

Published
December 1, 2024
Journal
JAMA Psychiatry
Authors
Hinkle, J. T., Graziosi, M., Nayak, S., Yaden, D. B.

Clinical Trials

0 trials

No clinical trials have been tagged with both 5-MeO-DMT and Equity and Ethics yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all 5-MeO-DMT papers Search all Equity and Ethics trials Full 5-MeO-DMT profile Full Equity and Ethics profile